Federal Register / Vol. 88, No. 196 / Thursday, October 12, 2023 / Notices 70681 

be sent to Pita Gomez using the contact 

information listed above at least 5 

business days before the meeting 

date(s). 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Pita 

Gomez using the contact information 

listed above at least 10 business days 

before the meeting(s) they wish to 

attend. Since all in-person meetings will 

occur in a federal government building, 

attendees must go through a security 

check to enter the building. Non-U.S. 

Citizen attendees must notify HRSA of 

their planned attendance at least 20 

business days prior to the meeting to 

facilitate their entry into the building. 

All attendees are required to present 

government-issued identification prior 

to entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2023–22584 Filed 10–11–23; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Heritable Disorders in Newborns and 

Children 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Committee on Heritable Disorders in 

Newborns and Children (ACHDNC or 

Committee) has scheduled a public 

meeting to be held on Thursday, 

November 2, 2023, and Friday, 

November 3, 2023. Information about 

the ACHDNC and the agenda for this 

meeting can be found on the ACHDNC 

website at https://www.hrsa.gov/ 

advisory-committees/heritabledisorders/index.html. 

DATES: Thursday, November 2, 2023, 

from 10:00 a.m. to 4:00 p.m. Eastern 

Time (ET) and Friday, November 3, 

2023, from 10:00 a.m. to 2:00 p.m. ET. 

ADDRESSES: This meeting will be held 

via webinar. While this meeting is open 

to the public, advance registration is 

required. 

Please visit the ACHDNC website for 

information on registration: https://

www.hrsa.gov/advisory-committees/ 

heritable-disorders/index.html by the 

deadline of 12:00 p.m. ET on November 

1, 2023. Instructions on how to access 

the meeting via webcast will be 

provided upon registration. 

FOR FURTHER INFORMATION CONTACT: 

Alaina Harris, Maternal and Child 

Health Bureau, HRSA, 5600 Fishers 

Lane, Room 18W66, Rockville, 

Maryland 20857; 301–443–0721; or 

ACHDNC@hrsa.gov. 

SUPPLEMENTARY INFORMATION: ACHDNC 

provides advice and recommendations 

to the Secretary of Health and Human 

Services (Secretary) on the development 

of newborn screening activities, 

technologies, policies, guidelines, and 

programs for effectively reducing 

morbidity and mortality in newborns 

and children having, or at risk for, 

heritable disorders. ACHDNC reviews 

and reports regularly on newborn and 

childhood screening practices, 

recommends improvements in the 

national newborn and childhood 

screening programs, and fulfills 

requirements stated in the authorizing 

legislation. In addition, ACHDNC’s 

recommendations regarding inclusion of 

additional conditions for screening on 

the Recommended Uniform Screening 

Panel, following adoption by the 

Secretary, are evidence-informed 

preventive health services provided for 

in the comprehensive guidelines 

supported by HRSA pursuant to section 

2713 of the Public Health Service Act 

(42 U.S.C. 300gg–13). Under this 

provision, non-grandfathered group 

health plans and health insurance 

issuers offering non-grandfathered 

group or individual health insurance are 

required to provide insurance coverage 

without cost-sharing (a co-payment, coinsurance, or deductible) for preventive 

services for plan years (i.e., policy years) 

beginning on or after the date that is 1 

year from the Secretary’s adoption of the 

condition for screening. 

During the November 2–3, 2023, 

meeting, ACHDNC will hear from 

experts in the fields of public health, 

medicine, heritable disorders, rare 

disorders, and newborn screening. 

Agenda items include the following: 

(1) An update on the Krabbe disease 

expedited evidence review update; 

(2) An update on the Duchenne 

Muscular Dystrophy evidence review 

update; 

(3) An update by the ACHDNC 

Decision Matrix ad hoc topic group and 

potential vote on revisions to the 

ACHDNC Decision Matrix; 

(4) A presentation and discussion on 

the ACHDNC’s conflict of interest 

procedures; 

(5) Ad hoc topic group updates; and 

(6) A possible presentation on the 

National Academies of Sciences, 

Engineering, and Medicine Workshop 

on Next Generation Screening. 

ACHDNC will not vote on 

recommending conditions for inclusion 

in the Recommended Uniform 

Screening Panel during this meeting; 

however, Krabbe disease and Duchenne 

Muscular Dystrophy evidence review 

updates along with a discussion and a 

potential vote on revisions to the 

ACHDNC Decision Matrix may inform 

such potential future recommendations. 

Agenda items are subject to change as 

priorities dictate. Information about 

ACHDNC, including a roster of members 

and past meeting summaries, is 

available on the ACHDNC website. 

Members of the public will have the 

opportunity to provide comments on 

any or all of the above agenda items. 

Public participants may request to 

provide general oral comments and may 

submit written statements in advance of 

the scheduled meeting. Oral comments 

will be honored in the order they are 

requested and may be limited as time 

allows. Members of the public registered 

to provide oral public comments on all 

other newborn screening related topics 

are tentatively scheduled to provide 

their statements on Thursday, 

November 2, 2023. Requests to provide 

a written statement or make oral 

comments to ACHDNC must be 

submitted via the registration website by 

12:00 p.m. ET on Friday, October 20, 

2023. Written comments will be shared 

with the Committee, so that they have 

an opportunity to consider them prior to 

the meeting. 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Alaina 

Harris at the address and phone number 

listed above at least 10 business days 

prior to the meeting. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2023–22493 Filed 10–11–23; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Infant and Maternal Mortality 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 


ddrumheller on DSK120RN23PROD with NOTICES1